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Autosomal dominant polycystic kidney disease: new treatment
options and how to test their efficacy
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) represents a slowly progressing cystic kidney
disorder which evolves into end-stage renal disease in the majority of patients. Currently, there are no
established treatments to retard the progression of the disease, but several promising therapeutic options
are being tested in ongoing clinical trials. An inherent dilemma for the investigation of therapies in
ADPKD is the dissociation of the early onset and constant rate of cyst growth from the delayed but
accelerated loss of renal function. In order to prevent the latter, one needs to act on the former, i.e.
current belief by experts in the field is that (1) retardation of cyst growth will ultimately improve the
loss of glomerular filtration rate, and (2) cyst volume is an ideal surrogate parameter for outcome in
early ADPKD. The present review will discuss the utility and the techniques for kidney and cyst volume
measurements to assess disease progression in ADPKD, and summarizes ongoing clinical trials testing
novel therapeutic options.
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 Autosomal Dominant Polycystic Kidney Disease – 
The Most Frequent Hereditary Renal Disease 
 Autosomal dominant polycystic kidney disease
(ADPKD) is a well-known chronically progressing cystic 
renal disease. Approximately 1: 800 to 1: 1,000 people are 
affected by the disease, although there are areas where 
the incidence of this condition is more or less frequent. 
The disease is inherited in an autosomal dominant fash-
ion, progresses slowly over decades, and manifests clini-
cally with hypertension, flank pain, hematuria and renal 
cyst infections in adults. Extrarenal manifestations are 
common but rarely prominent in early disease. The 
pathogenesis of ADPKD is characterized by cyst develop-
ment and growth in both kidneys  [1, 2] . Typically, the size 
of the kidneys increases from a normal size (150–200 
cm 3 )  [3] in adolescence to  1 1,500 cm 3 /kidney. The grow-
ing cysts gradually replace the functional renal paren-
chyma and distort the normal architecture of the kidney. 
Despite the presence of innumerable cysts in both kid-
neys, glomerular filtration rate (GFR) is well preserved in 
most patients up to the age of 30–40 years. Between the 
ages of 40 and 70 years, however, renal function usually 
declines in an accelerated fashion. End-stage renal dis-
ease (ESRD) with the need for dialysis or transplantation 
affects approximately 50% of the patients with ADPKD 
by the age of 70 years  [4] .
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 Abstract 
 Autosomal dominant polycystic kidney disease (ADPKD) 
represents a slowly progressing cystic kidney disorder which 
evolves into end-stage renal disease in the majority of pa-
tients. Currently, there are no established treatments to re-
tard the progression of the disease, but several promising 
therapeutic options are being tested in ongoing clinical tri-
als. An inherent dilemma for the investigation of therapies in 
ADPKD is the dissociation of the early onset and constant 
rate of cyst growth from the delayed but accelerated loss of 
renal function. In order to prevent the latter, one needs to 
act on the former, i.e. current belief by experts in the field is 
that (1) retardation of cyst growth will ultimately improve the 
loss of glomerular filtration rate, and (2) cyst volume is an 
ideal surrogate parameter for outcome in early ADPKD. The 
present review will discuss the utility and the techniques for 
kidney and cyst volume measurements to assess disease 
progression in ADPKD, and summarizes ongoing clinical tri-
als testing novel therapeutic options. 
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 In 85% of the cases, ADPKD is caused by mutations in 
the PKD1 gene which encodes the ciliary protein polycys-
tin-1. In 15%, the PKD2 gene which encodes polycystin-2 
is mutated. Mutations in other genes may account for 
some cases but have not yet been characterized. Cases 
with PKD1 gene mutations have a more severe course, 
with ESRD occurring at an average age of 54 years which 
is roughly 10 years earlier than in patients with mutations 
in the PKD2 gene. Thus, fewer patients with PKD2 muta-
tions reach ESRD during their lifetime  [5] .
 How to Follow Disease Progression:
GFR versus Cyst or Kidney Volume 
 Currently, changes in GFR are considered the gold 
standard for quantifying the progression rate in most 
chronic renal diseases. However, owing to the remarkable 
capability of intact nephrons to compensate for the loss 
of functional parenchyma, GFR measurement may fail to 
disclose ominous changes at early stages of kidney dis-
eases. In his classical paper, Dalgaard  [6] reported on 346 
individuals from Denmark with polycystic kidneys and 
found that palpable kidneys appeared in relatively young 
patients long before the onset of uremia. He concluded 
that cyst growth preceded and ultimately caused the 
 onset of uremia. Indeed, data from several longitudinal 
ADPKD cohort studies have now demonstrated that cyst 
volume growth represents a continuous process which 
begins in childhood or adolescence  [7–10] and precedes 
GFR decline by years  [11] , as shown in  figure 1 .
 Considering the grossly distorted kidney architecture 
at the time when GFR starts to decline, early intervention 
before cysts have replaced the bulk of intact renal paren-
chyma is probably warranted but a treatment effect on 
GFR would be evident only after several years. GFR is 
therefore not suitable as a primary end point for clinical 
studies testing early intervention. There is not much 
doubt that cyst growth is ultimately responsible for sub-
sequent loss of glomerular filtration through direct (com-
pression) and indirect (e.g. fibrosis) effects. Given the 
continuous rate of cyst growth during early ADPKD, kid-
ney or cyst volume enlargement is an obvious surrogate 
endpoint for clinical trials at that stage, and attempts have 
been made to correlate kidney volume progression with 
GFR decline in several longitudinal studies by serial im-
aging.
 Ultrasound is inaccurate for determining small chang-
es in renal volume and is not suitable for very large kid-
neys. Using a long observation period with an average of 
7.8 years of follow-up, however, Fick-Brosnahan et al.  [7] 
were able to demonstrate a significant inverse relation-
ship between the rate of kidney volume growth and the 
rate of GFR decline. Computed tomography (CT) has 
been used to monitor polycystic kidney volumes in sev-
eral studies  [12–14] . By combining data from a prospec-
tive and a retrospective study it could be shown that pa-
tients who develop renal insufficiency by the end of fol-
low-up exhibit a markedly higher volume growth  [11] . A 
concern related to the use of serial CT for disease moni-
toring in ADPKD is the repeated exposure of young pa-
tients to ionizing radiation. Therefore, magnetic reso-
nance imaging (MRI) based volumetry is emerging as the 
method of choice to follow kidney volumes.
 The Consortium for Radiologic Imaging Studies of 
Polycystic Kidney Disease (CRISP) has recently pub-
lished the results of yearly assessments of kidney and cyst 
volume measurements by MRI, and GFR by iothalamate 
clearance in 232 ADPKD patients who were followed over 
3 years  [9] . In that study, gadolinium-enhanced coronal 
T1-weighted images were obtained and the volumes of 
individual kidneys were measured using a stereologic 
method counting the intersections of the kidney outlines 
on a superimposed grid and summing the products of
the area measurements and slice thickness from the set
of contiguous images. A region-based threshold method 
was used to calculate cyst volumes from T2-weighted cor-
onal images. Although these patients had preserved renal 
function and no case of nephrogenic systemic fibrosis 
was reported in any of these patients, the CRISP investi-
gators moved to the use of image sequences obtained 
without gadolinium enhancement for further follow-up 
(CRISP II), and did not notice a change in accuracy of the 
volume measurements  [15] .
 In the CRISP study it was found that total kidney vol-
ume and total cyst volume increased exponentially with 
a mean ( 8 SD) annual growth rate of 5.3  8 3.9%. The 
baseline total kidney volume predicted the subsequent 
rate of increase in volume, independent of age. Further-
more, higher rates of kidney enlargement were found to 
be associated with a more rapid decrease in renal func-
tion. A baseline total kidney volume of  1 1,500 cm 3 in 51 
patients was associated with a decline in GFR by 4.3  8 
8.1 ml/min/year (p  ! 0.001)  [9] .
 We have recently validated and extended some of the 
results of the CRISP study in a Swiss cohort of young 
 ADPKD patients (age 18–42 years) with preserved GFR 
 [10] . Thus we were able to show that kidney volume 
changes could be reliably assessed with MRI within a 
time period as short as 6 months. Using a T1-weighted 
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acquisition protocol without gadolinium-based contrast 
agents we have examined 100 ADPKD patients at months 
0 and 6. The volumes of both kidneys were determined 
in each patient using a manual segmentation protocol. 
On each MRI section, the outlines of the kidneys were 
manually drawn and the renal volumes were calculated 
by multiplying all outline areas by the section thickness 
and summing the volume of each section.
 Using this approach we could detect a significant in-
crease in total kidney volume of 2.7  8 4.8% within 6 
months  [10] , corresponding to 5.4  8 9.5%/year, which is 
in very good agreement with the CRISP data. An interest-
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 Fig. 1.  a In patients with ADPKD the GFR 
remains preserved for decades, but de-
clines in an accelerated mode after the age 
of 40–50 years.  b The total kidney volume 
increases steadily throughout life in pa-
tients with ADPKD. Some patients show 
only slow progression (mostly PKD2 geno-
type), whereas others progress more rap-
idly. Copyright © 2008 Massachusetts 
Medical Society. All rights reserved. 
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ing observation was that some patients displayed a sig-
nificant volume regression which could be attributed to 
spontaneous rupture of large cysts. Like the CRISP study, 
we found a high degree of correlation between total kid-
ney volume change and cyst volume change, demonstrat-
ing that the total kidney volume growth can be entirely 
attributed to the growth of the cysts. Because the mea-
surement of total kidney volume is much easier and more 
reliable than that of cyst volume, the former might be a 
more precise marker of disease progression.  Table 1 sum-
marizes  the  characteristics  and the kidney volume 
growth rates of the Swiss and the American ADPKD co-
horts. A high degree of similarity in terms of baseline 
characteristics, total kidney volume, and volume growth 
rates can be noted.
 Taken together, there is a growing body of evidence 
that kidney volume changes can reliably be measured in 
early ADPKD and that cyst and kidney volume growth is 
directly correlated with a subsequent loss of GFR. How-
ever, the correlation was not perfect in these studies. This 
might be due to some measurement errors of GFR and 
kidney volume, as well as the difficulties adjusting for the 
heterogeneity of study subjects in terms of baseline age 
and normalizing kidney volume and GFR to body size. In 
addition, modifying factors might also affect GFR inde-
pendent of their influence on cyst growth. Although kid-
ney volume is not a perfect surrogate marker for studying 
early disease progression in ADPKD, at present it is cer-
tainly the best, in particular for proof-of-principle studies 
that need to rely on reasonable follow-up times.
 Current Therapeutic Approaches for ADPKD 
 The pathogenesis of cyst growth in ADPKD is complex 
and involves multiple signaling cascades  [16–18] . Based 
on experimental research data, clinical trials have been 
initiated to examine the efficacy of various drugs which 
interfere with these signaling pathways in ADPKD, in-
cluding the mammalian target of rapamycin (mTOR) in-
hibitors rapamycin (Rapamune  ) and everolimus (Certi-
can  ), the vasopressin V2 receptor antagonist OPC-41061 
(Tolvaptan  ), and the somatostatin analog octreotide-
LAR (Sandostatin LAR  ). Furthermore, a large study is 
testing the effect of inhibition of the renin-angiotensin-
aldosterone system (RAAS), using ACEI (angiotensin-
converting enzyme inhibitor) and ARB (aldosterone re-
ceptor blocker) therapy.  Table 2 summarizes the most 
important ongoing trials. Based on pathophysiological 
considerations and experimental animal models, some 
other drugs have been proposed, but these substances 
have not yet reached the stage of clinical trials and will 
not be discussed further.
 Use of mTOR Inhibitors to Treat ADPKD Disease 
Progression 
 A hallmark of ADPKD is enhanced renal tubular epi-
thelial cell proliferation. In various animal models of 
PKD and in human ADPKD the aberrant epithelial cell 
proliferation has clearly been linked to an activation of 
the mTOR pathway  [19–22] . Furthermore, a direct phys-
ical interaction between the cytoplasmic tail of polycys-
tin-1 (PC1) and tuberin (the product of the TSC2 gene 
that is known to regulate the kinase activity of mTOR) 
could be demonstrated  [18] . Mutations in PC1 are thought 
to inappropriately promote the proliferation of cyst-lin-
ing epithelial cells in ADPKD via mTOR  [23] . Hence, a 
therapy with mTOR inhibitors represents a promising 
strategy to inhibit the aberrant activation of the mTOR 
pathway in ADPKD. Both mTOR inhibitors rapamycin 
and everolimus have been shown to significantly retard 
the cyst growth and to preserve the renal function in sev-
eral animal models of PKD  [19–22] .
 Currently 4 prospective, randomized clinical trials 
with rapamycin and everolimus are in progress, and are 
summarized in  table 2 . Data on several additional case 
series have reported promising results at scientific meet-
ings, some of which have been published in abstract form. 
Three of the 4 trials use kidney (cyst) volume change as 
the primary endpoint. These 4 trials are different in terms 
Table 1. Characteristics and cyst growth rates in the Swiss [10] 
and American [9] ADPKD studies
Swiss ADPKD
cohort
CRISP cohort
Number of patients 100 232
Age, years (range) 31.286.4 (18–42) 32.488.9 (15–46)
Female, % 37 60
GFR or creatinine
clearance, ml/min 110826 107828
Baseline TKV, cm3 1,0038568 1,0768670
Annual TKV increase
In cm3 62.28136.5 63.4869.8
In % 5.3689.47 5.2783.92
The characteristics of the Swiss and American ADPKD co-
horts were similar. Kidney volume growth and growth rates were 
also alike. TKV = Total kidney volume.
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of patient number, patient characteristics and dose range 
used. The SUISSE ADPKD study (NCT00346918) en-
rolled 100 patients aged 18–40 years with preserved renal 
function and uses sirolimus at 2 mg/day for 18 months 
 [24] . A German study (NCT00414440) enrolled 400 pa-
tients aged 18–65 years with CKD stage II/III and uses 
everolimus for 2 years at a higher dose. The Cleveland 
Clinic (NCT00286156) and the Bergamo (NCT00491517) 
studies involve a smaller patient population, using a dose-
finding strategy. Definitive data from these 4 clinical tri-
als will be available in 2010.
 Use of Vasopressin V2 Receptor Antagonists to Treat 
ADPKD Disease Progression 
 In addition to increased cell proliferation which may 
be targeted by mTOR inhibition, fluid secretion into 
cysts is thought to play a central role in the process of cyst 
enlargement. Fluid secretion and cell proliferation are 
driven in part by alterations in intracellular calcium 
 homeostasis and cyclic adenosine monophosphate 
(cAMP) levels. These alterations can be explained by the 
fact that polycystin-1 and polycystin-2, the latter being a 
calcium-permeable cation channel, function together in 
specialized structures that sense the extracellular envi-
ronment, such as primary cilia, focal adhesions and ad-
herens complexes. Thus, hormone receptors such as the 
vasopressin V2 receptor which drive cAMP production 
in the kidney appear to be logical treatment targets. The 
V2 receptor antagonists (V2RA) OPC-31260 and tolvap-
tan inhibit cyst development in an animal model of PKD 
(Pkd–/tm1Som mouse, orthologous to human PKD2)  [25] . 
Consistent with the lack of V2 receptor expression in liv-
er tissue, V2RA had no effect on liver cysts.
 The Tolvaptan Efficacy and Safety in Management of 
PKD and Outcomes (TEMPO) trial program consists of 
several studies. The results of the phase 2 studies sug-
Table 2. Most important ongoing clinical trials testing drug efficacy on disease progression in ADPKD
Study name Study number Study drug Study design Eligibility Patients
n
Treatment 
duration, months
SUISSE NCT00346918 Sirolimus Single center 18–40 years old 100 18
ADPKD 2 mg/day Randomized GFR >70 ml/min
Open-label
SIRENA NCT00491517 Sirolimus Single center 18–80 years old 16 6
Randomized GFR >40 ml/min
Open-label
Crossover
Sirolimus NCT00286156 Sirolimus Single center 18–75 years old 45 12
in ADPKD Randomized I: GFR >60 ml/min
Open-label II: GFR 25–59 ml/min
Dose comparison
Everolimus NCT00414440 Everolimus Multicenter 18–65 years old 400 24
in ADPKD Randomized GFR 30–90 ml/min
Placebo-controlled
Tempo 3/4 NCT00428948 Tolvaptan Multicenter 18–40 years old 1,200–1,500 36
trial phase 3 Randomized GFR >70 ml/min
Placebo-controlled
ALADIN NCT00309283 Somatostatin Single center >18 years old 66 36
trial Randomized GFR >70 ml/min
Single blind
HALT-PKD NCT00283686 Lisinopril/Telmisartan vs. Multicenter 15–49 years old 548 48
study A Lisinopril/placebo and Randomized GFR >60 ml/min
low vs. standard BP Placebo-controlled BP >130/80 mm Hg
HALT-PKD NCT00283686 Lisinopril/Telmisartan vs. Multicenter 18–64 years old 472 Time to
study B Lisinopril/placebo Randomized GFR 25–60 ml/min endpoint
Placebo-controlled
 Autosomal Dominant Polycystic Kidney 
Disease 
Kidney Blood Press Res 2009;32:380–387 385
gested that tolvaptan is safe and well tolerated in ADPKD 
 [26] . A large phase 3, placebo-controlled, double-blind 
study in 18- to 50-year-old patients with ADPKD and 
preserved renal function but relatively rapid progression, 
as  indicated by a total kidney volume of  1 750 ml, has 
been initiated and will determine whether tolvaptan is 
effective in slowing the progression of the disease (TEM-
PO 3/4 study; NCT00428948).
 Use of Somatostatin Analogs to Treat ADPKD 
Progression 
 Somatostatin receptors are present in human kidneys 
 [27] and influence chloride secretion via CFTR chan-
nels. Having observed stabilization of cyst volume in an 
ADPKD patient with pituitary adenoma who received so-
matostatin, Ruggenenti et al.  [28] hypothesized that this 
agent might be beneficial in ADPKD. In a small cross-
over placebo-controlled pilot study, 12 patients were 
treated with somatostatin for 6 months and kidney vol-
ume growth was assessed by CT volumetry. During treat-
ment with somatostatin, the percent increase in total kid-
ney volume was significantly lower and cystic volume 
tended to increase less. A phase 3, single center, random-
ized controlled study enrolling 66 patients  1 18 years with 
GFR  1 40 ml/min/1.73m 2 is now ongoing to validate these 
results using kidney volume change assessed by MRI as 
primary outcome (the ALADIN trial; NCT00309283). 
Furthermore, two trials have evaluated the effect of oc-
treotide or another long-acting somatostatin analog, lan-
reotide, on polycystic liver volume (NCT00426153, which 
assesses kidney volume as a secondary endpoint, and 
NCT00565097, which has recently been completed and 
showed a small but significant effect on polycystic liver 
volume over 6 months  [29] ).
 Blood Pressure Control with ACEI and ARB to Treat 
ADPKD Progression 
 Hypertension occurs early in patients with ADPKD 
and before the loss of renal function, and activation of 
the RAAS may play a role in the pathogenesis of hyper-
tension as well as in the pathogenesis of cyst progression 
 [30] . Thus, drugs that block the RAAS (renin inhibitors, 
ACEIs, ARBs, or aldosterone antagonists) could be reno-
protective also in ADPKD. A few studies have previous-
ly tested the use of ACEIs in ADPKD. In a non-random-
ized study, hypertensive ADPKD patients treated with a 
diuretic had a faster GFR decline than those treated with 
ACEIs  [31] . As compared with the calcium channel 
blocker amlodipine, enalapril significantly reduced pro-
teinuria in hypertensive ADPKD patients in a random-
ized trial but had no effect on GFR decline  [32] . The only 
placebo-controlled trial testing an ACEI in ADPKD 
showed no benefit  [33] . However, these studies all in-
cluded relatively old patients and used GFR as primary 
outcome. A recent study tested the use of ACEI in chil-
dren with ADPKD and used kidney volume by ultraso-
nography as primary outcome. There was no significant 
treatment effect on renal growth in that study  [34] .
 The HALT-PKD trial is an ongoing multicenter study 
designed to test whether blockade of RAAS and/or rigor-
ous blood pressure control play a role in slowing renal 
progression during early and late phases in ADPKD 
(NCT00283686)  [35] . In this prospective randomized 
controlled trial the independent effects of RAAS block-
ade using both ACEI and ARB as well as blood pressure 
lowering on renal disease progression in early (study A; 
GFR,  1 60 ml/min; n = 548) and more advanced renal dis-
ease (study B; GFR, 25–60 ml/min; n = 472) are being 
tested. The ACEI lisinopril is prescribed for all patients 
in HALT (both studies A and B). Since it is not known 
whether the addition of an ARB, telmisartan, will pro-
vide renal or cardiovascular protection in ADPKD pa-
tients, patients in both studies A and B will be random-
ized to lisinopril plus placebo versus lisinopril plus 
 telmisartan. In study A, hypertensive and borderline 
 hypertensive ( 1 130/80 mm Hg) ADPKD subjects 15–50 
years of age are randomized in a 2  ! 2 factorial design to 
lisinopril (ACEI) and placebo versus ACEI and telmisar-
tan (ARB) and two levels of blood pressure control: stan-
dard (120–130/70–80 mm Hg) versus rigorous goal (95–
110/65–75 mm Hg). Study A uses a primary structural 
endpoint, change in total kidney volume over 4 years by 
MRI, as developed in CRISP. In study B, hypertensive and 
borderline hypertensive ADPKD subjects 18–65 years of 
age with GFR 25–60 ml/min are randomized to ACEI 
and placebo versus ACEI and ARB therapy with a single 
blood pressure goal of 110–130/80 mm Hg. The primary 
outcome is time to the composite endpoints of doubling 
of serum creatinine, ESRD, or death. Thus, in the HALT 
studies the relative benefits of blood pressure control and 
inhibition of the RAAS in both early and late stages of 
ADPKD will be established, which will guide clinicians 
regarding best practices for ADPKD patients.
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 Conclusions 
 ADPKD progression can be reliably assessed by MR 
and CT imaging techniques and kidney volumetry. These 
procedures can be used to test the effect of new investi-
gational drugs in early stages of the disease, when GFR is 
still preserved. In later stages of the disease, progression 
could be monitored by following the decline of GFR, but 
at that time therapeutic intervention might be too late to 
significantly affect outcome.
 There is reasonable hope that disease progression in 
patients with ADPKD can be delayed with newer thera-
peutic approaches which are currently being tested. At 
present, four treatment approaches which have been 
based on novel pathophysiological insights and animal 
data have been transferred to randomized clinical trials. 
Results from these ongoing studies will become available 
in 2010. Until then patients with ADPKD need to be ad-
vised to follow the current management recommenda-
tions, which at this time include optimal blood pressure 
control, sufficient fluid intake and avoidance of smoking 
and excessive caffeine intake. 
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